Abstract
We present an integrated docking environment that allows for iterative and interactive detailed analysis of many docking solutions. All docking information is stored in an ORACLE database. New scoring schemes (e.g. target-specific scoring functions) as well as various types of filters can be easily defined and tested within this environment. As an example application we investigated the validity of the following hypothesis: If a docking procedure can lead to enrichments significantly better than random then a bias towards (partially) correct placements should be detectable. Such bias in terms of a preference for certain interacting groups within the active site can be used to select a set of receptor-based pharmacophore constraints, which in turn might be used to enhance the docking procedure. As a proof of concept for this approach we performed docking studies on three targets: thrombin, the cyclin-dependent kinase 2 (CDK2) and the angiotensin converting enzyme (ACE). We docked a set of known active compounds with standard FlexX and derived three sets of target-specific receptor-based pharmacophore constraints by statistical analysis of the predicted placements. Applying these receptor-based constraints in a virtual screening protocol utilizing FlexXPharm led to significantly improved enrichments.
Keywords: virtual screening, docking, target-tailored scoring, pharmacophore, flexx-pharm, oracle, ace, cdk2, thrombin
Current Drug Discovery Technologies
Title: The FlexX Database Docking Environment - Rational Extraction of Receptor Based Pharmacophores
Volume: 1 Issue: 1
Author(s): Holger Claussen, Marcus Gastreich, Volker Apelt, Jonathan Greene, Sally A. Hindle and Christian Lemmen
Affiliation:
Keywords: virtual screening, docking, target-tailored scoring, pharmacophore, flexx-pharm, oracle, ace, cdk2, thrombin
Abstract: We present an integrated docking environment that allows for iterative and interactive detailed analysis of many docking solutions. All docking information is stored in an ORACLE database. New scoring schemes (e.g. target-specific scoring functions) as well as various types of filters can be easily defined and tested within this environment. As an example application we investigated the validity of the following hypothesis: If a docking procedure can lead to enrichments significantly better than random then a bias towards (partially) correct placements should be detectable. Such bias in terms of a preference for certain interacting groups within the active site can be used to select a set of receptor-based pharmacophore constraints, which in turn might be used to enhance the docking procedure. As a proof of concept for this approach we performed docking studies on three targets: thrombin, the cyclin-dependent kinase 2 (CDK2) and the angiotensin converting enzyme (ACE). We docked a set of known active compounds with standard FlexX and derived three sets of target-specific receptor-based pharmacophore constraints by statistical analysis of the predicted placements. Applying these receptor-based constraints in a virtual screening protocol utilizing FlexXPharm led to significantly improved enrichments.
Export Options
About this article
Cite this article as:
Claussen Holger, Gastreich Marcus, Apelt Volker, Greene Jonathan, Hindle A. Sally and Lemmen Christian, The FlexX Database Docking Environment - Rational Extraction of Receptor Based Pharmacophores, Current Drug Discovery Technologies 2004; 1 (1) . https://dx.doi.org/10.2174/1570163043484815
DOI https://dx.doi.org/10.2174/1570163043484815 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Pulmonary Arterial Hypertension
Current Vascular Pharmacology Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study
Cardiovascular & Hematological Disorders-Drug Targets Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Structure and Function in COPD
Current Respiratory Medicine Reviews Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Theoretical and Evidence-Based Benefit of Afterload Reduction in the Postoperative Pediatric Heart
Current Vascular Pharmacology Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Brain Perfusion In Sepsis
Current Vascular Pharmacology Recent Advances and Patents on Chest Drainage Systems
Recent Patents on Biomedical Engineering (Discontinued) Sensors and Energy Harvesters Utilizing the Magnetoelastic Principle: Review of Characteristic Applications and Patents
Recent Patents on Electrical & Electronic Engineering Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Mitochondrial Dysfunction during Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Interaction of Small Cationic Peptides with Intact Basement Membranes. A Study Using Intrinsic Optical Signals of Chick Retinas
Current Medicinal Chemistry The Plasma and Tissue Kininogen-kallikrein-kinin System: Role in the Cardiovascular System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Future Challenges for Microsomal Transport Protein Inhibitors
Current Vascular Pharmacology